Follow
International Journal of Current Microbiology and Applied Sciences (IJCMAS)
IJCMAS is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCMAS Articles.
Index Copernicus ICI Journals Master List 2019 - IJCMAS--ICV 2019: 96.39 For more details click here
National Academy of Agricultural Sciences (NAAS) : NAAS Score: *5.38 (2020) [Effective from January 1, 2020]For more details click here

Login as a Reviewer

Indexed in



National Academy of Agricultural Sciences (NAAS)
NAAS Score: *5.38 (2020)
[Effective from January 1, 2020]
For more details click here

ICV 2019: 96.39
Index Copernicus ICI Journals Master List 2019 - IJCMAS--ICV 2019: 96.39
For more details click here

See Guidelines to Authors
Current Issues
Download Publication Certificate

Original Research Articles

PRINT ISSN : 2319-7692
Online ISSN : 2319-7706
Issues : 12 per year
Publisher : Excellent Publishers
Email : editorijcmas@gmail.com / submit@ijcmas.com
Editor-in-chief: Dr.M.Prakash
Index Copernicus ICV 2018: 95.39
NAAS RATING 2020: 5.38

Int.J.Curr.Microbiol.App.Sci.2022.11(4): 73-77
DOI: https://doi.org/10.20546/ijcmas.2022.1104.011


Effect of Guanabenz-Loaded Nanoparticles on the Mortality Rate of Mice Infected with Chronic Toxoplasmosis
Wesam Moustafa Abdelhamid Elgendy1*, Yusuf Ahmed Yusuf Haggag2,Kholoud Abd Allah El-Nouby1, Samy Ibrahim El-Kowrany1 and Sirria Mostafa El Marhoumy1
1Department of Medical Parasitology, Faculty of Medicine, Tanta University, Egypt
2Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Egypt
*Corresponding author
Abstract:

Chronic toxoplasmosis is considered as one of the major neglected tropical diseases. Although there are many treatment modalities for acute toxoplasmosis, there is still insufficient knowledge about a safe effective treatment for chronic toxoplasmosis till now. However, guanabenz has shown a promising result for treatment of Toxoplasma gondii infection although it could not completely eradicate all brain tissue cysts. This study was designed to test the effect of guanabenz-loaded polyethylene glycol poly lactic-co-glycolic acid (PEG PLGA) nanoparticles on mortality rate of mice infected with chronic toxoplasmosis. The study was conducted in Tanta University, Medical Parasitology laboratory on 160 mice that were divided as follows: Group I (five subgroups each of 20 mice): Ia: non-infected non-treated, Ib: infected untreated, Ic: non-infected mice given nanoparticles alone, Id: infected mice given nanoparticles alone and Ie: infected mice treated by pyrimethamine (4 mg/kg) and sulfadiazine (100 mg/kg). Group II (three subgroups each of 20 mice): IIa: Infected and treated mice with guanabenz alone (5mg/kg/day), IIb: Infected and treated mice with guanabenz-loaded nanoparticles by full dose and IIc: Infected and treated mice with guanabenz-loaded nanoparticles by the half dose (2.5 mg/kg/day). The drugs were given on day 25 post-infection for 19 successive days. On the 20th day the mortality rate was calculated in different subgroups. The data were processed statistically. The Results showed that although guanabenz-loaded nanoparticles were given by intraperitoneal injection which carries much more infection hazards and stress on the mice, it caused less mortality rate in mice than subgroup Ie which was given pyrimethamine and sulfadiazine combination therapy orally, however this was of no statistically significant difference. It could be concluded that guanabenz-loaded PEG-PLGA nanoparticles cause no increase in the mortality rate of mice infected with chronic toxoplasmosis.


Keywords: Toxoplasma gondii, mortality rate, tissue cysts, nanoparticles
Download this article as Download

How to cite this article:

Wesam Moustafa Abdelhamid Elgendy, Yusuf Ahmed Yusuf Haggag, Kholoud Abd Allah El-Nouby, Samy Ibrahim El-Kowrany and Sirria Mostafa El Marhoumy. 2022. Effect of Guanabenz-Loaded Nanoparticles on the Mortality Rate of Mice Infected with Chronic Toxoplasmosis.Int.J.Curr.Microbiol.App.Sci. 11(4): 73-77. doi: https://doi.org/10.20546/ijcmas.2022.1104.011